B+
Bull case
20%
Probability
Target price
$7.50
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
QNTM
Quantum Biopharma Subordinate Voting SharesDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
FDA clearance removes a major regulatory gate for Lucid-MS, while lower expenses and reported liquidity reduce immediate financing pressure. Successful Phase 2 execution or supportive imaging data could materially re-rate the stock from its approximately $24 million market capitalization.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +8.9.
What can break
Additional financing may be required, and digital-asset values may be volatile or illiquid.
Momentum
2
Value
41
Sentiment
60
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.40 · Bull $7.50 · Bear $1.30Analysis 2026-09-03; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-03 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $8.00
Why
Momentum2 · Δ7d -0.4
Value41 · Δ7d 0.0
Sentiment60 · Δ7d +8.9
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +8.9.
Contradictions & invalidation
- • Additional financing may be required, and digital-asset values may be volatile or illiquid.
- • Low coverage, loose peers, and microcap trading volatility reduce signal quality and increase downside risk.
- • Lucid-MS still lacks demonstrated patient efficacy, and Phase 2 enrollment, cost, regulatory, and clinical-outcome risks remain substantial.
Catalyst clock
2026-08-14
Q2 cost reduction and liquidity update
Lead driver: Sentiment · See AI snapshot
Momentum
2
9% active weight
Current posture
7d trendFlat
Δ7d
-0.4
Δ21d
-
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
60
62% active weight
Current posture
7d trendImproving
Δ7d
+8.9
Δ21d
-
Why this grade
Composite grade D. Momentum 1.9 / Value 41.2 / Sentiment 60.3
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-03. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$3.40
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$1.30
Analysis reference price unavailable
Analysis 2026-09-03 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$23.98M
Beta
0.79
Shares Out
6.4M
P/E (TTM) · Derived
-0.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-3.27
Rev YoY
-
EPS YoY
-84.0%
Gross Margin
-
Op Margin
-
Net Debt
-$4.3M
Current Ratio
1.20
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data